Summary.-The cytocidal properties of metronidazole against hypoxic mammalian cells are described. This chemotherapeutic action has been shown to be dependent on drug concentration and duration of exposure. The x-ray TCD50 for a murine anaplastic carcinoma was reduced from 6081 rad to 4643 rad when animals were given metronidazole orally for 36 h before radiation treatment. The effect is attributed to the direct killing of hypoxic tumour cells by a mechanism analogous to that proposed for the action of the drug on anaerobic micro-organisms. It is concluded that further work with metronidazole as a cytotoxin specific for hypoxic cells is warranted, particularly in view of the reported lack of toxicity associated with the preliminary clinical use of the drug as a radiosensitizer in man.
METRONIDAZOLE (Flagyl, May and
Baker Ltd) has been shown to be an effective radiosensitizer of several murine tumour systems in vivo (Begg, Sheldon and Foster, 1974; Stone and Withers, 1974; Rauth and Kaufman, 1975) . Preliminary clinical trials using drug doses of about 200 mg/kg are now being undertaken (Urtasun et al., 1974 (Urtasun et al., , 1975 Deutsch et al., 1975) .
The drug was originally screened as a radiosensitizer of hypoxic cells because it is an organic nitro-compound possessing extremely favourable pharmacological and toxicological properties, which had been emphasized several years earlier as important prerequisites for sensitizing activity in vivo (Emmerson and Howard-Flanders, 1965 ). In addition the drug is well known for its potent cytocidal action on anaerobic but not aerobic microorganisms (McFadzean, 1971) .
Subsequent experiments have indicated that the drug does have an analogous chemotherapeutic effect on hypoxic tumour cells. The rates of growth of tumours of mice given metronidazole following radiation treatment have been found to be lower, and the rates of cell loss higher, than those of animals given radiation alone (Begg et al., 1974; Inch and McCredie, 1975) . The drug had also been found to kill non-cycling, mammalian cells grown in vitro as spheroids (Sutherland, 1974) . It was thus apparent that prolonged continuous treatment with metronidazole before and during the first part of fractionated radiotherapy might provide an additional method of attacking the problem of radioresistant hypoxic tumour cells (Foster and Willson, 1976) .
We now report experiments on mouse tumours in which this possibility of using metronidazole as a chemotherapeutic agent has been further evaluated. 6 h at 37°C whilst being gently shaken to ensure that the cells remained in suspension, and that they continued to be in equilibrium with the appropriate gas. After the required intervals 0-2 ml aliquots of the cell suspension (4 x 106 cells) were injected into groups of 5 or 10 CBA/CA mice from the inbred Brunel colony. The times of death of the mice were recorded.
(b) Tumour control probability determination.-Syngeneic female CBA/Ht mice were used in batches of 100. A fast-growing anaplastic carcinoma, designated NT, was transplanted subcutaneously by trocar on to the ventral surface of the thorax whilst the animals were under Penthrane-induced anaesthesia.
The resulting tumours were measured twice a week with Vernier calipers and those mice with tumours of approximately 5 mm diameter were selected for use. Each selected batch was divided into two: one half was set aside and 2 days later these mice were assigned to one of 6 radiation dose groups. The other half was given an oral dose of metronidazole (0.3 mg/g body wt.) every 6 h for 36 h (6 administrations) and irradiated 6-8 h after the last drug dose. All the mice were irradiated as described previously (Begg et al., 1974) with 240 kV x-rays (HVL 1-3 mm Cu) at a dose rate of 240 rad/min whilst breathing air at room temperature. The mice were then kept for 130 days. Those mice developing tumours greater than 8 mm in diameter were scored as recurrences. The x-ray dose required to cure 50% of the mice (TCD50) and the s.e. mean of this value was calculated from the percentage cures using a computer program (Peters and Porter, private communication). The program assumes that single cell survival kinetics apply so that the probability of tumour control is given by exp (-SN) where N is the initial number of clonogenic cells and S is the recurring (i.e. surviving) fraction which is an exponentially decreasing function of dose.
Another batch of tumour-bearing mice was dosed with metronidazole as described above. At hourly intervals, for up to 8 h, groups of 3 or 4 mice were exsanguinated by heart puncture whilst under ether-induced anaesthesia. The concentration of metronidazole in the serum from these blood specimens was measured by polarography (Kane, 1961 (Fig. 1) that for a dose of 5300 rad less than 20% of the control mice were cured compared with over 80% of the drug-treated mice.
The serum concentration/time curve (Fig. 2) indicates that the serum concentration of metronidazole at the time of irradiation was less than 30 ,tg/ml. The peak concentration of the drug was in the region of 200 ,tg/ml and the halflife of metronidazole in the serum was approximately 1N h. No mice were lost from this study due to drug toxicity. However, 8/64 animals from the drugtreated group were excluded from the experiment due to the development of metastases, mainly in the lungs, and similarly 15/101 from the control group. Also, 9 mice died within 3 weeks of irradiation due to the unavoidable occasional inclusion of part of the intestine in the radiation field in a few cases.
DISCUSSION AND CONCLUSION
The results of the incubation of ascites cells with metronidazole in vitro clearly shows that the drug is cytocidal for anoxic cells at concentrations producing little or no effect on aerated cells. It has been reported (Hawes, Howard and Gray, 1964) that incubation of ascites cells under anaerobic conditions with or without mechanical agitation greatly reduces the viability of these cells and increases their radiosensitivity. In the present study no reduction was seen in the survival time of mice injected with cells incubated under anoxic conditions for up to 6 h when compared with the analogous aerated controls. How- It is not possible to make a quantitative estimate of the fraction of cells killed by the drug treatment schedules used in this experiment. However, there can be little doubt that the increased survival time of the mice receiving the drug-treated cells is due to a substantial reduction of the viable fraction of the standard cell inoculum. Since these studies were begun a similar effect of metronidazole against anoxic mammalian cells has been reported (Mohindra and Rauth, 1976) . Nitrofurazone was found to be similarly active. In vitro experiments also showed that the activity is dependent on cell type, 02 concentration, temperature of incubation and concentration of both drugs. Recently a 2-nitroimidazole drug has also been found to be cytocidal for anoxic mammalian cells (Hall and Roizin-Towle, 1975) . ,tg/ml. Results from studies with fractionated irradiations led to the suggestion that exposure to the drug between doses of radiation prevents the repair of sublethal radiation damage.
The increased sensitivity of the solid carcinoma to x-rays reported here is interpreted as beiig due to the killing of a substantial fraction of the hypoxic cells in the tumour by the metronidazole treatment before irradiation. For significant radiosensitization of hypoxic cells to occur in vitro (Asquith et al., 1974) or in vivo (Rauth and Kaufman, 1975) it has been found that metronidazole concentrations 5 times greater than the value of 30 ,ag/ml found in the present study are required at the time of irradiation.
Unfortunately, the fast growth rate of murine tumours of the type used in this experiment restricts the time available for pre-irradiation treatment with a drug. In particular, the short half-life of metronidazole in mice (11 h) means that either the drug has to be administered very frequently or very high drug doses have to be used to maintain an effective drug concentration over an extended time period. The design of the experiments reported here took these factors into account as far as possible. It is not known how fast hypoxic cells are generated in the tumour used nor the minimum effective concentration of metronidazole under in vivo conditions. Therefore, it is possible that some hypoxic tumour cells survived the treatment schedule used. For these reasons further experiments have been started where metronidazole has been administered for a time after irradiation as well as before and in which a range of drug doses has been used. The serum half-life of metronidazole in man is 8-10 h and the growth rate of most solid human neoplasms is much slower than their murine counterparts. Thus any future clinical application will be more straightforward than might be suggested by the present experiments. The drug regimes reported are directly applicable only to mice.
It is probable that many organic nitro-aromatic compounds have activity against anoxic mammalian cells. On reduction, whether by radiation or biochemically, they can form a toxic species (Willson, Cramp and Ings, 1974; Willson and Searle, 1975; Foster and Willson 1976) . In the case of metronidazole this species is either inactivated by 02 or only produced in its absence; hence the drug's lack of activity on aerobic microorganisms (Ings, McFadzean and Ormerod, 1974) , or on normal well-oxygenated cells as reported herein. Thus, as with radiosensitizers, drugs which show the greatest efficiency on hypoxic cells in vitro (i.e. having relatively high oneelectron electrode potentials), are more likely to produce unacceptable side-effects in vivo.
In conclusion we suggest that the use of metronidazole as a cytotoxin specific for hypoxic cells in solid tumours should be more fully explored. The lack of unwanted side-effects recently reported following its use as a radiosensitizer, in man at high doses, is encouraging (Urtasun et al., 1975) . In addition, the use of the drug as a chemotherapeutic agent before the commencement of radiotherapy would obviate the necessity of altering well established fractionation schedules to accommodate tolerable drug regimes.
